Nordstrom, Inc. (JWN) managed to rebound with the stock climbing 0.52% or $0.29 to close the day at $56.35 on light trading volume of 2.86M shares, compared to its three month average trading volume of 3.19M. The Seattle Washington 98101 based company has been outperforming the apparel stores group over the past 52 weeks, with the stock gaining 3.15%, compared to the industry which has dropped -2.55% over the same period. With RSI of 54.82, the stock should still continue to rise and get closer to its one year target estimate of $54.78, making it a hold for now.
Nordstrom, Inc., a fashion specialty retailer, offers apparel, shoes, cosmetics, and accessories for men, women, and children in the United States and Canada. It operates through two segments, Retail and Credit. The Retail segment offers a selection of brand name and private label merchandise through various channels, including Nordstrom branded full-line stores and online store at Nordstrom.com; Nordstrom Rack stores; Nordstromrack.com and HauteLook; and other retail channels, including Trunk Club showrooms and TrunkClub.com, Jeffrey boutiques, and clearance store that operates under the name Last Chance. The Credit segment operates Nordstrom fsb, a federal savings bank, which provides a private label credit card, two Nordstrom VISA credit cards, and a debit card. Its credit and debit cards feature a shopping-based loyalty program. As of November 18, 2016, the company operated 348 stores in 40 states, including 123 full-line stores in the United States, Canada; and Puerto Rico; 215 Nordstrom Rack stores; 2 Jeffrey boutiques; and 2 clearance stores. Nordstrom, Inc. also sells its products through catalogs. The company was founded in 1901 and is based in Seattle, Washington.
Take-Two Interactive Software Inc. (TTWO) grew with the stock adding 3.32% or $1.61 to close at $50.09 on active trading volume of 2.84M compared its three months average trading volume of 1.88M. The New York New York 10012 based company operating under the Multimedia & Graphics Software industry has been trending up for the last 52 weeks, with the shares price now 41.62% up for the period and up by 43.77% so far this year. With price target of $51.29 and a 59.73% rebound from 52-week low, Take-Two Interactive Software Inc. has plenty of upside potential, making it a hold with a view buy.
Take-Two Interactive Software, Inc. develops, publishes, and markets interactive entertainment solutions for consumers worldwide. The company offers its products under the Rockstar Games and 2K labels. It develops and publishes action/adventure products under the Grand Theft Auto, Max Payne, Midnight Club, and Red Dead names through developing sequels; offering downloadable episodes, and content and virtual currency; and releasing titles for smartphones and tablets. The company also develops brands in other genres, including the L.A. Noire, Bully, and Manhunt franchises. In addition, it publishes various entertainment properties across platforms and a range of genres, including action, adventure, family/casual, racing, role-playing, shooter, sports, and strategy; various unit selling franchises, including BioShock, Borderlands, Carnival Games, Evolve, Mafia, NBA 2K, Sid Meier’s Civilization, Spec Ops, WWE 2K, and XCOM; and various sports simulation titles, including its flagship NBA 2K series, a basketball video game and the WWE 2K professional wrestling series. The company’s products are designed for console gaming systems, such as Sony’s PlayStation 3 and PlayStation 4, and Microsoft’s Xbox 360 and Xbox One; and personal computers comprising smartphones and tablets. It delivers its products through physical retail, digital download, online platforms, and cloud streaming services. Take-Two Interactive Software, Inc. was founded in 1993 and is headquartered in New York, New York.
Tonix Pharmaceuticals Holding Corp. (TNXP) failed to extend gains with the stock declining -5.88% or $-0.03 to close the day at $0.4 on higher than average trading volume of 2.83M shares, compared to its three month average trading volume of 1.23M. The New York New York 10022 based company has been underperforming the drug manufacturers – major companies by -83.744% for last three months and its recent losses have pulled the stock down -94.78% YTD, versus the drug manufacturers – major industry which is down -1.41% for the same period. The RSI of 36.67 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.
Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, develops medicines for common disorders of the central nervous system. The company’s lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden. Its lead product candidate includes TNX-102 SL, a cyclobenzaprine HCl sublingual tablet, a Phase III clinical stage for the treatment of PTSD; and Phase II clinical stage for the treatment of military-related PTSD. The company also develops TNX-301, a fixed dose combination drug product that contains disulfiram and selegiline for the treatment of alcohol use disorders, as well as biodefense development programs for protection from smallpox virus and radiation injury. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in New York, New York.